Gyeyee Shin, MD
Family Medicine · Bridgeport, CTNPI 1861621005
Payments from drug & device makers
Across 157 payments — averaging $17.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$658
- AstraZeneca$296
- GSK$225
- Lilly USA, LLC$217
- Amgen$190
- Novo Nordisk$170
- plus $959 from 19 others
What the payments were for
- Consulting fees$1756%
- Speaking & faculty fees$1827%
- Food & beverage$2,32185%
- Education$381%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 53 | $658 |
| AstraZeneca | 14 | $296 |
| GSK | 12 | $225 |
| Lilly USA, LLC | 15 | $217 |
| Amgen(2 entities) | 2 | $190 |
| Novo Nordisk | 12 | $170 |
| Sanofi-aventis U.S. LLC | 4 | $159 |
| Sanofi | 3 | $105 |
| AbbVie(2 entities) | 6 | $99 |
| Novartis | 4 | $74 |
| Radius Health, Inc. | 3 | $68 |
| Merck | 4 | $67 |
| Mylan Specialty L.p. | 3 | $66 |
| Regeneron Healthcare Solutions, Inc. | 3 | $57 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $52 |
| Sunovion Pharmaceuticals Inc. | 3 | $42 |
| Jazz Pharmaceuticals Inc. | 2 | $27 |
| Ultragenyx Pharmaceutical Inc. | 2 | $27 |
| Pfizer | 1 | $20 |
| Optinose US, Inc. | 1 | $19 |
| Philips North America LLC | 1 | $19 |
| Johnson & Johnson | 1 | $17 |
| Ironwood Pharmaceuticals, Inc | 1 | $15 |
| Exact Sciences | 1 | $14 |
| Sumitomo Pharma America, Inc. | 2 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prolia$175
How this compares
$2,715 in reported general payments places this provider in the 80th percentile of 588 family medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 66 | $154,411 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 84 | $67,862 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 47 | $62,423 |
| JardianceEmpagliflozin | 36 | $59,434 |
| LinzessLinaclotide | 53 | $50,652 |
| MyrbetriqMirabegron | 41 | $43,394 |
| EliquisApixaban | 32 | $42,308 |
| JanuviaSitagliptin Phosphate | 26 | $42,066 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 40 | $40,733 |
| RybelsusSemaglutide | 14 | $38,437 |
| FarxigaDapagliflozin Propanediol | 21 | $33,935 |
| ProliaDenosumab | 19 | $33,807 |
| Xigduo XrDapaglifloz Propaned/Metformin | 24 | $32,765 |
| GemtesaVibegron | 21 | $30,915 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 25 | $27,090 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $170 | $192,84880 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance | $658 | $121,85783 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $225 | $92,459128 claims |
| MerckJanuvia, Janumet Xr, Dulera | $67 | $87,62078 claims |
| AbbVieLinzess, Synthroid | $99 | $54,00485 claims |
| Lilly USA, LLCMounjaro, Trulicity | $217 | $53,00931 claims |
| PfizerEliquis | $20 | $42,30832 claims |
| AstraZenecaFarxiga | $296 | $33,93521 claims |
| AmgenProlia | $190 | $33,80719 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $13 | $30,91521 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $159 | $27,09025 claims |
| Johnson & JohnsonXarelto | $17 | $9,12711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 588 family medicine providers in Connecticut.
Other family medicine in Bridgeport
- Sanjeev RaoBridgeport$27K
- Awais MalikBridgeport$16K
- Debra GramlichStamford$292K
- Hadrian HolderNew Haven$213K
- Theodore BrunoDurham$201K
- Kenneth DardickStorrs$146K
- Raymond KurkerSouth Windsor$107K
- Thao DoranMarlborough$102K
- Raja FattalehPutnam$53K
- Nicholas TzikasNew Haven$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.